Beihai Gofar Hits Day Low at CNY 4.85 Amid Price Pressure

Beihai Gofar Chuanshan Biological Co., Ltd. has experienced a significant decline today, with the stock dropping by 7.21%. The stock reached an intraday low of CNY 4.85, reflecting ongoing challenges within the company. Over the past week, the stock has seen a steep decline of 16.7%, and its performance over the last month shows a decrease of 15.69%. In comparison, the China Shanghai Composite index has also faced losses, but at a lesser rate of 2.06% for the day and 3.15% for the week. Year-to-date, Beihai Gofar has underperformed the index, with a decline of 20.1% compared to the composite's modest drop of 1.39%. Financial metrics indicate a low Return on Capital Employed (ROCE) of 1.02%, suggesting limited profitability relative to capital invested. Additionally, the company has reported a negative operating profit growth rate of 254.98% over the past five years, highlighting ongoing financial difficulties. With a market capitalization of CNY 2,791 million, Beihai Gofar continues to navigate a challenging landscape in the pharmaceuticals and biotechnology sector.